InvestorsHub Logo
Followers 35
Posts 1771
Boards Moderated 0
Alias Born 09/25/2012

Re: A deleted message

Sunday, 05/05/2019 10:06:31 AM

Sunday, May 05, 2019 10:06:31 AM

Post# of 232963
I will tell this to everyone, I believe the biggest problem for CytoDyn is remaining on the OTC for trading. That's what's killing the company and the stock price. A revere split should be done and it should start to trade on the NASDAQ. Now before you scream at me or ignore me, hear me out.

Right now the price is low at .40 cents per share, so the company to get financing has to keep diluting at this low of a stock price. Then there is the massive float that keeps building up. If the company lists on the NASDAQ and does a reverse split then it could be able to dilute at say $6 per share or $7 per share and get a lot more money for a lot less shares.

Then you have the outstanding shares issue. Either way the company is eventually going to have to do a reverse stock split. That many outstanding shares for a company is not feasible in the long run.

Finally, the only reason why I think CytoyDyn is staying on the OTC is because SEC Filings are not monitored. The OTC doesn't have the same rules for public companies as the NASDAQ has. If there is an issue with financials in OTC, the exchange doesn't care. However, NASDAQ will notify the company. In other words, CytoDyn gets to be more lax when it comes to financials not being known. That's my 2 cents on the matter. I think the CEO means well, but he is hurting the company by not uplisting now.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News